EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

A newly identified immune escape mechanism in AML involves the surface marker SLAMF6, which is upregulated in approximately 60% of patients. This marker shields leukemic cells from T-cell–mediated immune responses. In this MEDtalk, Carl Sandén from Lund University (Sweden) presents preclinical data on a novel SLAMF6-blocking antibody that restores T-cell recognition and leads to potent elimination of AML cells.